At FDA: A Study In Staying Power

The ability of David Kessler, the 41-year-old commissioner of the Food and Drug Administration, to survive the purge of Bush appointees by the Clinton administration is an achievement being greeted with praise by some in the pharmaceutical, food, and biotechnology industries; and measured disappointment by some manufacturers of medical devices. Kessler was asked to retain his position by the Clinton administration in February. He took the reins of the agency in December 1990, and at that tim

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Kessler was asked to retain his position by the Clinton administration in February. He took the reins of the agency in December 1990, and at that time announced he would engage in major reorganizing efforts to revitalize and reinvigorate the agency. Previously, FDA had been criticized for its slow enforcement of laws and regulations. But whether or not those efforts, which included appointing new section heads and reorganizing major departments, are perceived as successful depends on one's industry segment, says John Villforth, director of the Food and Drug Law Institute, a nonprofit organization based in Washington, D.C., that monitors FDA.

According to Villforth, the passage of user-fee legislation in the 102nd Congress, with the strong support of Kessler, is giving these industries hope that in the future, FDA approval times will considerably lessen. User fees amount to a payment of $100,000 this year, increasing to $233,000 in five years, to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Ron Kaufman

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio